{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:36:33Z","timestamp":1784698593371,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":417,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin cardiac amyloidosis (ATTR-CA) is most often associated with heart failure with preserved ejection fraction (HFpEF). However, patients may present with impaired systolic function at the time of diagnosis, which has not been widely investigated. We sought to explore the prevalence of various heart failure (HF) phenotypes and their associated clinical characteristics at the time of ATTR-CA diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a single-centre retrospective cohort study of consecutive patients with ATTR-CA evaluated between February 2016 and December 2022. Data on patient demographics, comorbidities, imaging and laboratory findings were compared across HF phenotypes (age: 78.1 \u00b1 8.6 years, with 91.1% male). A total of 21.6% (n = 46) presented with heart failure with reduced ejection fraction (HFrEF), 17.8% (n = 38) with heart failure with mildly reduced ejection fraction (HFmrEF) and 60.6% (n = 129) with HFpEF at the time of diagnosis with ATTR-CA. Those presenting with HFrEF or HFmrEF were more likely to be African American and had significantly worse New York Heart Association (NYHA) functional class, higher N-terminal pro-brain natriuretic peptide (NT-proBNP) and higher serum creatinine levels as compared with those with HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although ATTR-CA is traditionally thought to be seen primarily among patients with HFpEF, our data suggest that ATTR-CA has a higher prevalence among patients with HFrEF, which underscores the importance of heightened clinical suspicion regardless of ejection fraction when considering ATTR-CA. Furthermore, although comorbidities are similar, patients with HFmrEF and HFrEF had a worse symptom burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15035","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:38:24Z","timestamp":1724485104000},"page":"3649-3655","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Transthyretin Cardiac Amyloid: Broad Heart Failure Phenotypic Spectrum and Implications for Diagnosis"],"prefix":"10.1093","volume":"11","author":[{"given":"Mileydis","family":"Alonso","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika K.","family":"Neicheril","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Manla","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi , Abu Dhabi ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm L.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lafave","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelenis","family":"Seijo De Armas","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Lewis","family":"Camargo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipan","family":"Uppal","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wolinsky","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Thakkar-Rivera","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Velez","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Baran","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D.","family":"Estep","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Snipelisky","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida , Weston, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"2026012113115158900_ehf215035-bib-0001","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026012113115158900_ehf215035-bib-0002","volume-title":"Transthyretin amyloid cardiomyopathy (ATTR-CM)","author":"Jain","year":"2021"},{"key":"2026012113115158900_ehf215035-bib-0003","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012113115158900_ehf215035-bib-0004","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR amyloidosis: Current and emerging management strategies: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Griffin","year":"2021","journal-title":"Cardio Oncology"},{"key":"2026012113115158900_ehf215035-bib-0005","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40256-022-00563-4","article-title":"Real-world characteristics of patients with wild-type transthyretin amyloid cardiomyopathy: An analysis of electronic healthcare records in the United States","volume":"23","author":"Bhambri","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026012113115158900_ehf215035-bib-0006","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026012113115158900_ehf215035-bib-0007","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012113115158900_ehf215035-bib-0008","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jaccao.2021.05.004","article-title":"Two decades of cardiac amyloidosis: A Danish nationwide study","volume":"3","author":"Westin","year":"2021","journal-title":"Cardio Oncology."},{"key":"2026012113115158900_ehf215035-bib-0009","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s12350-020-02098-0","article-title":"High prevalence of heart failure with reduced ejection fraction in patients with transthyretin cardiac amyloidosis","volume":"27","author":"Asif","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026012113115158900_ehf215035-bib-0010","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.hlc.2022.08.002","article-title":"Prevalence and risk factors of cardiac amyloidosis in heart failure: A systematic review and meta-analysis","volume":"31","author":"See","year":"2022","journal-title":"Heart Lung Circ"},{"key":"2026012113115158900_ehf215035-bib-0011","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jchf.2022.06.006","article-title":"Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function","volume":"10","author":"Martyn","year":"2022","journal-title":"Heart Fail"},{"key":"2026012113115158900_ehf215035-bib-0012","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.cardfail.2022.03.095","article-title":"Heart failure with reduced ejection fraction: An under-appreciated clinical phenotype of transthyretin cardiac amyloid (ATTR-CA)","volume":"28","author":"Bhattacharya","year":"2022","journal-title":"J Card Fail"},{"key":"2026012113115158900_ehf215035-bib-0013","doi-asserted-by":"publisher","DOI":"10.1161\/circ.142.suppl_3.161","article-title":"Reduced ejection fraction at diagnosis is an independent predictor of mortality in transthyretin amyloid cardiomyopathy","volume":"142","author":"Bukhari","year":"2020","journal-title":"Circulation"},{"key":"2026012113115158900_ehf215035-bib-0014","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012113115158900_ehf215035-bib-0015","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113115158900_ehf215035-bib-0016","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11899-021-00626-4","article-title":"Amyloidosis with cardiac involvement: Identification, characterization, and management","volume":"16","author":"Jamal","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"2026012113115158900_ehf215035-bib-0017","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026012113115158900_ehf215035-bib-0018","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026012113115158900_ehf215035-bib-0019","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012113115158900_ehf215035-bib-0020","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.cardfail.2020.09.372","article-title":"Guideline-directed medical therapy may not be harmful in patients with transthyretin cardiac amyloidosis and heart failure with reduced ejection fraction","volume":"26","author":"Rohm","year":"2020","journal-title":"J Card Fail"},{"key":"2026012113115158900_ehf215035-bib-0021","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2026012113115158900_ehf215035-bib-0022","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026012113115158900_ehf215035-bib-0023","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24298","article-title":"Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis","volume":"47","author":"McDonald","year":"2024","journal-title":"Clin Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3649\/64516923\/eschf_11_6_3649.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3649\/64516923\/eschf_11_6_3649.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:13:55Z","timestamp":1769019235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/3649\/8269338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,24]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15035","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}